<DOC>
	<DOCNO>NCT01250366</DOCNO>
	<brief_summary>The purpose study determine Safety Pharmacokinetics Multiple Ascending Oral Doses INX-08189 Chronically-infected Genotype 1 HCV , Treatment-naïve Subjects .</brief_summary>
	<brief_title>Study Safety &amp; PK INX-08189 Chronically-infected HCV , Treatment-naïve Subjects</brief_title>
	<detailed_description>This multi-center , sequential-cohort , double-blind , placebo-controlled , multiple ascend dose , 7-day treatment study chronically-infected genotype 1 HCV , treatment-naïve subject . Primary Objectives include : Safety • evaluate safety ascend oral dos INX-08189 give day seven ( 7 ) day chronically-infected genotype 1 HCV , treatment-naïve subject Pharmacokinetic • characterize pharmacokinetic ( PK ) profile multiple ascend oral dos INX-08189 chronically-infected genotype 1 HCV , treatment-naïve subject Pharmacodynamic • evaluate relationship metric reduction baseline serum HCV RNA PK parameter INX-08189 metabolite INX-08032 Efficacy • measure maximal reduction plasma HCV RNA ascend oral dose level INX-08189 give day seven ( 7 ) day chronically-infected genotype 1 HCV , treatment-naïve subject</detailed_description>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>At screen visit ( Visit 1 ) , subject meet follow criterion : 1 . Males &amp; female , 18 65 year age inclusive ( BMI least 18kg/m2 exceed 36kg/m2 ) ; 2 . Diagnosis chronic HCV 1 previous PCR result prior screening , positive HCV viral load least 100,000IU/ml screen measure quantitative PCR ; 3 . HCV genotype 1 per central lab test report ; 4 . HCV treatmentnaïve ( defined prior treatment interferon , pegylated interferon , ribavirin , HCV direct act antiviral drug ) ; 5 . Liver biopsy consistent chronic HCV infection noncirrhotic judge pathologist ( Knodell &lt; 3 , Metavir &lt; 2 , Ishak &lt; 4 , Batts &amp; Ludwig &lt; 2 ) within last 2 year &amp; Visit 2 ( biopsy do within screen period ) ; 6 . Negative urine drug screen drug abuse screen Study Day 1 ( methadone use allow ) ; 7 . Females negative serum βHCG pregnancy test screening &amp; negative urine dipstick pregnancy test upon entry clinical unit Study Day 1 ; 8 . Agreement female childbearing potential &amp; male ( surgically sterilize ) practice acceptable method birth control . Surgical sterilization either female male partner must occur least 6 month prior first dose &amp; female must postmenopausal 2 year consider nonchildbearing potential . Acceptable contraceptive method include 1 follow : Oral &amp; implantable hormonal contraceptive female least 3 month prior 1st dose Study Drug , IUD place least 6 month prior first dose , barrier method either diaphragm condom spermicide . ( Abstinence acceptable method birth control , subject indicate sexual inactivity must agree utilize birth control event sexual activity ) ; 9 . Willing &amp; able complete study visit procedure , &amp; able communicate investigator &amp; personnel ; 10 . Signed informed consent form ( ICF ) execute prior protocol screen assessment At screen visit subject meet follow criterion : 1 . Advanced liver disease , cirrhosis , sign decompensated liver disease variceal bleeding , ascites , hepatic encephalopathy , active jaundice ( total bilirubin &gt; 2 , evidence decompensated liver disease ; 2 . Coinfection HBV HIV ( positive test HBsAg antiHIV Ab ) ; 3 . Acute cardiac ischemia , unstable heart disease clinically symptomatic cardiac abnormality apparent ECG &amp; PE , QTcB interval Visit 1 ≥ 450ms Bazette 's correction , personal family history Torsades de pointes ; 4 . Use following medication concurrently within 30 day prior Screening associate QT prolongation : macrolides , antiarrhythmic agent , azoles , fluoroquinolones , &amp; tricyclic antidepressant ( methadone use allow ) ; 5 . Use immunosuppressive immunemodulating agent ( include corticosteroid &amp; immunosuppressive agent ) presence immunologicallymediated autoimmune disease ( asthma ) history organ transplantation ( inhaled steroid asthma &amp; topical steroid minor skin condition allow ) ; 6 . Use strong CYP3A4inhibiting protease inhibitor ( specifically atazanavir , indinavir , nelfinavir , saquinavir , &amp; ritonavir ) , strong CYP3A4 inhibitor ( specifically clarithromycin , itraconazole , ketoconazole , nefazodone , telithromycin ) , strong CYP3A4 inducer ( specifically rifampin , efavirenz , etravirine , phenobarbital , phenytoin , &amp; carbamazepine ) ; 7 . Absolute NEUT count &lt; 1800 cells/mm3 ( &lt; 1500 cells/mm3 African Americans ) , platelet count &lt; 130,000 cells/mm3 , hemoglobin &lt; 11g/dl woman &lt; 13g/dl men ; 8 . A history abnormal thyroid function adequately control ( define TSH level &lt; 0.8 x LLN &gt; 1.2 x ULN ) ; 9 . Serum creatinine concentration &gt; 1.5 time upper limit normal , albumin &lt; 3g/dl ; 10 . Presence history severe , uncontrolled , hospitalizationrequiring psychiatric disease include severe depression , suicide attempt severity psychosis ; 11 . Any malignancy within last 5 year treat cervical carcinoma situ treat basal cell carcinoma 20 % risk recurrence within 2 year ; 12 . Alcohol abuse ( investigator assessment ) within past 2 year alcohol use pattern interfere study conduct ; 13 . Drug abuse ( investigator assessment ) within last 6 month exception methadone ; 14 . Current lactation breastfeeding ; 15 . Major surgery within 30 day prior Visit 1 ; 16 . Participation another clinical trial investigational drug device within 6 month prior visit 1 ; 17 . Donation blood plasma within 30 day prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Safety Pharmacokinetics</keyword>
</DOC>